JP2006514627A5 - - Google Patents

Download PDF

Info

Publication number
JP2006514627A5
JP2006514627A5 JP2004552884A JP2004552884A JP2006514627A5 JP 2006514627 A5 JP2006514627 A5 JP 2006514627A5 JP 2004552884 A JP2004552884 A JP 2004552884A JP 2004552884 A JP2004552884 A JP 2004552884A JP 2006514627 A5 JP2006514627 A5 JP 2006514627A5
Authority
JP
Japan
Prior art keywords
use according
hapten
enzyme
target
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004552884A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006514627A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2003/004994 external-priority patent/WO2004045642A1/en
Publication of JP2006514627A publication Critical patent/JP2006514627A/ja
Publication of JP2006514627A5 publication Critical patent/JP2006514627A5/ja
Pending legal-status Critical Current

Links

JP2004552884A 2002-11-15 2003-11-17 治療薬の標的化送達のための多重特異的非共有結合複合体の使用 Pending JP2006514627A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42637902P 2002-11-15 2002-11-15
PCT/GB2003/004994 WO2004045642A1 (en) 2002-11-15 2003-11-17 Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics

Publications (2)

Publication Number Publication Date
JP2006514627A JP2006514627A (ja) 2006-05-11
JP2006514627A5 true JP2006514627A5 (cg-RX-API-DMAC10.html) 2006-09-28

Family

ID=32326341

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004552884A Pending JP2006514627A (ja) 2002-11-15 2003-11-17 治療薬の標的化送達のための多重特異的非共有結合複合体の使用

Country Status (6)

Country Link
US (1) US20040166115A1 (cg-RX-API-DMAC10.html)
EP (1) EP1560596A1 (cg-RX-API-DMAC10.html)
JP (1) JP2006514627A (cg-RX-API-DMAC10.html)
AU (1) AU2003283599C1 (cg-RX-API-DMAC10.html)
CA (1) CA2505717A1 (cg-RX-API-DMAC10.html)
WO (1) WO2004045642A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7591994B2 (en) 2002-12-13 2009-09-22 Immunomedics, Inc. Camptothecin-binding moiety conjugates
CA2531118C (en) * 2003-07-01 2013-01-08 Immunomedics, Inc. Multivalent carriers of bi-specific antibodies
US20050261170A1 (en) * 2004-01-22 2005-11-24 Immunomedics, Inc. Folate conjugates and complexes
US20060057062A1 (en) * 2004-09-10 2006-03-16 Trotter Dinko G Compositions and methods useful in pretargeted imaging
CN101171034B (zh) 2005-03-03 2014-06-18 免疫医疗公司 人源化l243抗体
PL3912643T3 (pl) 2009-02-13 2023-01-23 Immunomedics Inc. Immunokoniugaty z połączeniem rozszczepialnym wewnątrzkomórkowo
US9050375B2 (en) 2009-07-06 2015-06-09 Hoffmann-La Roche, Inc. Bi-specific digoxigenin binding antibodies
LT2544719T (lt) 2010-03-12 2019-10-25 Debiopharm Int Sa Cd37 surišančios molekulės, ir jų imunokonjugatai
AU2012236210B2 (en) 2011-04-01 2016-02-04 Immunogen, Inc. CD37-binding molecules and immunoconjugates thereof
SG11201407420RA (en) 2012-07-04 2015-02-27 Hoffmann La Roche Covalently linked antigen-antibody conjugates
EP2869837B1 (en) 2012-07-04 2016-09-14 F. Hoffmann-La Roche AG Anti-theophylline antibodies and methods of use
MX354303B (es) 2012-07-04 2018-02-23 Hoffmann La Roche Anticuerpos de anti-biotina y metodos de uso.
CR20160270A (es) 2013-12-20 2016-09-05 Hoffmann La Roche ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
WO2015101586A1 (en) 2014-01-03 2015-07-09 F. Hoffmann-La Roche Ag Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
BR112016014945A2 (pt) 2014-01-03 2018-01-23 F. Hoffmann-La Roche Ag conjugado, formulação farmacêutica e uso
EP3089758B1 (en) 2014-01-03 2021-01-27 F.Hoffmann-La Roche Ag Covalently linked helicar-anti-helicar antibody conjugates and uses thereof
EP3129065B1 (en) 2014-03-12 2026-05-13 Akamara Therapeutics, Inc. Targeted drug delivery through affinity based linkers
AR100978A1 (es) * 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
BR112017026027A2 (pt) 2015-06-08 2018-08-14 Debiopharm Int Sa combinações de imunoconjugado anti-cd37 e anticorpo anti-cd20
ES2809728T3 (es) 2015-06-24 2021-03-05 Hoffmann La Roche Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
JP6890581B2 (ja) 2015-08-28 2021-06-18 デビオファーム インターナショナル, エス. アー. Cd37の検出のための抗体およびアッセイ
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
AU2019277836A1 (en) 2018-05-30 2021-01-21 Debiopharm International, S.A. Anti-CD37 immunoconjugate dosing regimens
EP4744681A1 (en) * 2024-08-16 2026-05-20 Shanghai Bao Pharmaceuticals Co., Ltd. COMPLEX TARGETING TARGET CELLS AND ITS USE

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US7074405B1 (en) * 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
EP1113819B1 (en) * 1998-09-18 2011-02-23 Immunomedics, Inc. Antibody directed enzyme prodrug therapy (adept) with glucuronidase

Similar Documents

Publication Publication Date Title
CN114456186B (zh) 一种喜树碱类衍生物及其配体-药物偶联物
JP7458399B2 (ja) 抗クローディン抗体及びそれらの使用
JP2006518737A5 (cg-RX-API-DMAC10.html)
JP5084267B2 (ja) 多特異性抗体との使用のための治療および診断用コンジュゲート
JP4625637B2 (ja) 活性物質送達系及び活性物質を保護し投与する方法
JP2022113163A (ja) 核酸キャリア及び治療上の使用方法
Meyer et al. Site-specific prodrug activation by antibody-β-lactamase conjugates: Regression and long-term growth inhibition of human colon carcinoma xenograft models
CN110545846A (zh) 用于光免疫疗法的治疗组合物和相关方法
JP2009519931A5 (cg-RX-API-DMAC10.html)
AU2003283599C1 (en) Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics
JP2006511526A (ja) 細胞内で開裂可能な結合を有する免疫接合体
US20180271997A1 (en) Methods and Reagents to Treat Tumor and Cancer
CA2475395A1 (en) Anti-human tenascin monoclonal antibody
WO2018231661A1 (en) Methods and reagents to treat tumor and cancer
CN1946740B (zh) 抗人腱生蛋白单克隆抗体
US7833528B2 (en) Use of multispecific, non-covalent complexes for targeted delivery of therapeutics
Hay et al. Antibody-directed enzyme-prodrug therapy (ADEPT)
US20060002940A1 (en) Method of immunotherapy
Koumarianou et al. Development of a novel bi-specific monoclonal antibody approach for tumour targeting
Yamaguchi et al. Production, binding and cytotoxicity of human/mouse chimeric monoclonal antibody‐neocarzinostatin conjugate
JP4616991B2 (ja) 化学療法剤の標的特異的な毒性を増加させるための方法および組成物
EP4725508A1 (en) Ligand-drug conjugate having free payload recovery unit
WO2026098621A1 (zh) 工程改造的定点偶联抗体、抗体偶联药物及其应用
CA3297994A1 (en) Ligand-drug conjugate having free payload recovery unit
Bajic Treating colorectal cancer by targeting the carcinoembryonic antigen with immunocytokines and bispecific antibodies